🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Bart Barlogie

University of Arkansas for Medical Sciences

ORCID: 0000-0001-6116-1017
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells”.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

Blood(2002)10.1182/blood.v99.5.1745
N/A
0.969DataRank · unranked
637 citations

Johanna Hardin, Bob Kordsmeier, Klaus Bumm, Mingzhong Zheng, Erming Tian +17 more

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2119
N/A
0.456DataRank · unranked
8 citations

Rachael Sexton, Antje Hoering, Frits van Rhee, Bart Barlogie, Robert Z. Orlowski +1 more

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns

Blood Cancer Journal(2020)10.1038/s41408-020-0336-z
N/A
0DataRank · unranked
38 citations

Eileen M. Boyle, Cody Ashby, Yan Wang, Valeriy V. Lyzogubov, Christopher P. Wardell +16 more

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

Nature Communications(2022)10.1038/s41467-022-32145-y
N/A
0DataRank · unranked
76 citations

Carolina Schinke, Francesco Maura, Michael Bauer, Cody Ashby, Shayu Deshpande +11 more

The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States

Research Square(2022)10.21203/rs.3.rs-1177985/v1
N/A
0DataRank · unranked
0 citations

Leo Rasche, Carolina Schinke, Francesco Maura, Michael Bauer, Cody Ashby +11 more

A gene signature can predict risk of MGUS progressing to multiple myeloma

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01472-y
N/A
0DataRank · unranked
14 citations

Yan Cheng, Jun Ying, David E. Mery, Samer Al Hadidi, Visanu Wanchai +16 more

Data from Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

(2023)10.1158/1078-0432.c.6516871
N/A
0DataRank · unranked
0 citations

Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy, Bart Burington

Data from Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma

(2023)10.1158/1078-0432.c.6516871.v1
N/A
0DataRank · unranked
0 citations

Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy, Bart Burington

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Blood Cancer Journal(2020)10.1038/s41408-020-0311-8
N/A
0DataRank · unranked
252 citations

Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar +8 more